Professor of Interventional Cardiology

Tel: 0116 258 3035

Email: agershlick@aol.com

Address: Department of Cardiovascular Sciences, University of Leicester,  
Clinical Sciences Wing, Glenfield General Hospital, Leicester, LE3 9QP

For general enquiries, please email the secretary, Louise Goddard, or telephone 0116 258 3045

Recent Publications

Verheugt FW, Steinhubl SR, Hamon M, Darius H, Steg PG, Valgimigli M, Marso SP, Rao SV, Gershlick AH, Lincoff AM, Mehran R, Stone GW. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. JACC Cardiovasc Interv. 2011 Feb 4 2 191-7

Duckers HJ, Houtgraaf J, Hehrlein C, Schofer J, Waltenberger J, Gershlick A, Bartunek J, Nienaber C, Macaya C, Peters N, Smits P, Siminiak T, van Mieghem W, Legrand V, Serruys PW. Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention. 2011 Feb 6 7 805-12

Armstrong PW, Gershlick A, Goldstein P, Wilcox R, Danays T, Bluhmki E, Van de Werf F; STREAM Steering Committee. The Strategic Reperfusion Early After Myocardial Infarction (STREAM) study. Am Heart J. 2010 Jul 160 1 30-35

Talwar V, Wurm P, Bankart MJ, Gershlick AH, DE Caestecker JS. Clinical trial: chest pain due to presumed gastro-oesophageal reflux in coronary artery disease - controlled study of lansoprazole versus placebo. Aliment Pharmacol Ther. 2010  32  191-9

Remak E, Manson S, Hutton J, Brasseur P, Olivier E, Gershlick A. Cost-effectiveness of the Endeavor stent in de novo native coronary artery lesions updated with contemporary data. EuroIntervention. 2010 Feb 5 7 826-32

Alahmar A, Redwood S, Gershlick A. Retrograde approach to chronic total occlusions: can septal vessels be used more than once? J Invasive Cardiol. 2009 Dec 21 12 E234-6

Camenzind E, Wijns W, Mauri L, Boersma E, Parikh K, Kurowski V, Gao R, Bode C, Greenwood JP, Gershlick A, O'Neill W, Serruys PW, Jorissen B, Steg PG; PROTECT Steering Committee and Investigators. Rationale and design of the Patient Related OuTcomes with Endeavor versus Cypher stenting Trial (PROTECT): randomized controlled trial comparing the incidence of stent thrombosis and clinical events after sirolimus or zotarolimus drug-eluting stent implantation. Am Heart J. 2009 Dec 158 6 902-909

Carver A, Rafelt S, Gershlick AH, Fairbrother KL, Hughes S, Wilcox R; REACT Investigators. Longer-term follow-up of patients recruited to the REACT (Rescue Angioplasty Versus Conservative Treatment or Repeat Thrombolysis) trial. J Am Coll Cardiol. 2009 Jul 7 54 2 118-26

APPRAISE Steering Committee and Investigators, Alexander JH, Becker RC, Bhatt DL, Cools F, Crea F, Dellborg M, Fox KA, Goodman SG, Harrington RA, Huber K, Husted S, Lewis BS, Lopez-Sendon J, Mohan P, Montalescot G, Ruda M, Ruzyllo W, Verheugt F. Wallentin Apixaban, an oral, direct, selective factor Xa inhibitor, in combination with antiplatelet therapy after acute coronary syndrome: results of the Apixaban for Prevention of Acute Ischemic and Safety Events (APPRAISE) trial. Circulation. 2009 Jun 9 119 22 2877-85

Gershlick AH. Managing myocardial infarction in the elderly: time to bury inappropriate concerns instead. Eur Heart J. 2009 Apr 30 8 887-9

Serruys PW, Morice MC, Kappetein AP, Colombo A, Holmes DR, Mack MJ, Ståhle E, Feldman TE, van den Brand M, Bass EJ, Van Dyck N, Leadley K, Dawkins KD, Mohr FW; SYNTAX Investigators. Mooney M, Kroshus T, Zijlstra F, Boonstra PW, Vermeersch P, Van Cauwelaer. Percutaneous coronary intervention versus coronary-artery bypass grafting for severe coronary artery disease. N Engl J Med. 2009 Mar 5 360 10 961-72

Gershlick AH, Fearn S. Health economics: drug-eluting stents--are they worth the money? EuroIntervention. 2008 Aug 4 Suppl C C75-9

Werner GS, Di Mario C, Galassi AR, Gershlick A, Reimers B, Sianos G, Sievert H, Lefevre T, Reifart N; EuroCTO Club. Chronic total coronary occlusions and the occluded artery trial. A critical appraisal. EuroIntervention. 2008 May 4 1 23-7

Rubboli A, Halperin JL, Juhani Airaksinen KE, Buerke M, Eeckhout E, Freedman SB, Gershlick AH, Schlitt A, Fat Tse H, Verheugt FW, Lip GY. Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation. Ann Med. 2008  40 6 428-36

Gershlick AH. Contemporary percutaneous coronary intervention--30 years in the making. Clin Med. 2008 Apr 8 2 171-2

Veitch AM, Baglin TP, Gershlick AH, Harnden SM, Tighe R, Cairns S; British Society of Gastroenterology; British Committee for Standards in Haematology; British Cardiovascular Intervention Society. Guidelines for the management of anticoagulant and antiplatelet therapy in patients undergoing endoscopic procedures. Gut. 2008 Sep 57 9 1322-9

Gershlick AH. Ensuring appropriate use of antiplatelet agents in the treatment of acute coronary syndromes--have cardiovascular physicians been given enough grace in getting it right? Heart. 2008 Feb 94 2 135-7

Alp NJ, Gershlick AH, Carver A, Stevens SE, Wilcox R. Rescue angioplasty for failed thrombolysis in older patients: Insights from the REACT trial. Int J Cardiol 2008 Apr 10 125 2 254-7

Gershlick A, Kandzari DE, Leon MB, Wijns W, Meredith IT, Fajadet J, Popma JJ, Fitzgerald PJ, Kuntz RE; ENDEAVOR Investigators. Zotarolimus-eluting stents in patients with native coronary artery disease: clinical and angiographic outcomes in 1,317 patients. Am J Cardiol. 2007 Oct 22 100 8B 45M-55M

Denton-Beaumont RN, Banning AS, Gershlick AH. Malabsorption causing failure of pharmacological therapy in the treatment of atrial fibrillation. Int J Cardiol. 2007 Aug 29 128 3 e87-8

Gershlick AH, de Belder M, Chambers J, Hackett D, Keal R, Kelion A, Neubauer S, Pennell DJ, Rothman M, Signy M, Wilde P. Role of non-invasive imaging in the management of coronary artery disease: an assessment of likely change over the next 10 years. A report from the British Cardiovascular Society Working Group. Heart. 2007 Apr 93 4 423-31

Jeilan M, Richardson G, Gershlick A. Transvenous pacing causing tamponade in patients receiving glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention. J Invasive Cardiol. 2007 Feb 19 2 E40-2

Gershlick AH, Richardson G. Drug eluting stents. BMJ. 2006 Dec 16 333 7581 1233-4

Collet JP, Montalescot G, Le May M, Borentain M, Gershlick A. Percutaneous coronary intervention after fibrinolysis: a multiple meta-analyses approach according to the type of strategy. J Am Coll Cardiol. 2006 Oct 3 48 7 1326-35

Chitkara K, Hogrefe K, Vasa-Nicotera M, Swanson N, Gershlick AH. Eptifibatide-eluting stent as an antiproliferative and antithrombotic agent: in vitro evaluation. J Invasive Cardiol. 2006 Sep 18 9 417-22

Schampaert E, Moses JW, Schofer J, Schlüter M, Gershlick AH, Cohen EA, Palisaitis DA, Breithardt G, Donohoe DJ, Wang H, Popma JJ, Kuntz RE, Leon MB; SIRIUS, E- and C-SIRIUS Investigators. Sirolimus-eluting stents at two years: a pooled analysis of SIRIUS, E-SIRIUS, and C-SIRIUS with emphasis on late revascularizations and stent thromboses. Am J Cardiol. 2006 Jul 1 98 1 36-41

Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, Seth A, Sousa JE, Wijns W, Berge C, Deme M, Stoll HP; e-Cypher Investigators. Safety of coronary sirolimus-eluting stents in daily clinical practice: one-year follow-up of the e-Cypher registry. Circulation. 2006 Mar 21 113 11 1434-41

Gershlick AH, Stephens-Lloyd A, Hughes S, Abrams KR, Stevens SE, Uren NG, de Belder A, Davis J, Pitt M, Banning A, Baumbach A, Shiu MF, Schofield P, Dawkins KD, Henderson RA, Oldroyd KG, Wilcox R; REACT Trial Investigators. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med. 2005 Dec 29 353 26 2758-68

Gershlick AH. Is there any place for oral anti-restenotic treatment in the era of drug eluting stents? Heart. 2005 Nov 91 11 1377-9

Azeem T, Adlam D, Gershlick A. Evolution of vascular brachytherapy over time: data from the RENO-registry analysis. Int J Cardiol. 2005 Apr 20 100 2 225-8

Ng E, Jilaihawi H, Gershlick AH. Symptomatic myocardial bridging--a niche indication for drug-eluting stents? Int J Cardiol. 2005 Mar 30 99 3 463-4

Schlüter M, Schofer J, Gershlick AH, Schampaert E, Wijns W, Breithardt G; E- and C-SIRIUS Investigators. Direct stenting of native de novo coronary artery lesions with the sirolimus-eluting stent: a post hoc subanalysis of the pooled E- and C-SIRIUS trials. J Am Coll Cardiol. 2005 Jan 4 45 1 10-3

Links

Return to Cardiovascular Theme pages